Baxter signs blood pact with Laboratoire Francais du Fractionnement et des Biotechnologies (LFB):
This article was originally published in Clinica
French blood company Laboratoire Francais du Fractionnement et des Biotechnologies will distribute Baxter's HemAssist, an oxygen-carrying haemoglobin, in France. LFB has the monopoly on the production of blood derivatives from plasma collected in France. The two companies will invest Fr 200 million ($40 million) in a new production unit at LFB's Lille headquarters, for which Baxter will provide the production equipment. HemAssist is undergoing clinical trials on over 600 patients in the US and Europe and is expected to be launched by the beginning of 1998.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.